Other
Jun Zhu
Total Trials
5
Recruiting
1
Active
1
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
Failure Rate
20.0%
1 terminated/withdrawn out of 5 trials
Success Rate
0.0%
-86.5% vs industry average
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
1 recruiting
Enrollment Performance
Analytics
Phase 4
2(50.0%)
N/A
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 4(2)
N/A(1)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (5)
Showing 5 of 5 trials
NCT04295096Not ApplicableUnknown
Collection of PBMCs From Healthy Subjects for the Development of Cellular Immunotherapy Product
Role: lead
NCT03313271Recruiting
China Lymphoma Patient Registry Study
Role: lead
NCT02576327Phase 4Unknown
A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
Role: lead
NCT02487316Phase 4Withdrawn
A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib
Role: lead
NCT02399189Phase 2Unknown
MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma
Role: lead
All 5 trials loaded